Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...